Observational Study of Patients Older Than 60 Years With Acute Myeloblastic Leukemia (ALFA1200)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01966497

Recruitment Status : Unknown

Verified November 2017 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was: Recruiting

First Posted : October 21, 2013

Last Update Posted : November 20, 2017

Sponsor:

Information provided by (Responsible Party):

Assistance Publique - Hôpitaux de Paris

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	April 2019
Estimated Study Completion Date :	November 2019

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Gardin C, Pautas C, Fournier E, Itzykson R, Lemasle E, Bourhis JH, Adès L, Marolleau JP, Malfuson JV, Gastaud L, Raffoux E, Lambert J, Braun T, Thomas X, Chantepie S, Cluzeau T, de Botton S, Berthon C, Boissel N, Duployez N, Terré C, Peffault de Latour R, Michallet M, Celli-Lebras K, Preudhomme C, Dombret H. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood Adv. 2020 May 12;4(9):1942-1949. doi: 10.1182/bloodadvances.2019001349.

To Top